Ra-223 Improves Outcomes in Prostate Cancer With Bone Metastases

Article

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.

Radium-223 (Xofigo) produced low rates of treatment-related adverse effects and treatment discontinuation among patients with castration-resistant prostate cancer harboring bone metastases, according to data from a study presented at the 2023 Genitourinary Cancers Symposium.

The relatively low rate of treatment-related adverse events and lack of new safety concerns presented in this study demonstrates the safety of radium-223 under routine clinical practice in Taiwan treating bone metastases related to castration-resistant prostate cancer, according to the study authors.

The relatively low rate of treatment-related adverse events and lack of new safety concerns presented in this study demonstrates the safety of radium-223 under routine clinical practice in Taiwan treating bone metastases related to castration-resistant prostate cancer, according to the study authors.

© Dr_Microbe - stock.adobe.com.

Although researchers assessed treatment with radium-223 in the first-, second-, and third-line settings, patients treated in the first-line setting had fewer treatment-related adverse events and higher rates of treatment completion with 6 injections.

A total of 224 patients were included in the multicenter observational trial in Taiwan, of whom 97 were in the safety analysis set. Of these patients, 22 received radium-223 as first-line treatment, 42 as second-line treatment, and 33 as third-line treatment.

Previous lines of therapy included abiraterone and/or enzalutamide (Xtandi) (72.2%; n = 70) as well as docetaxel (34%; n = 33).

Of note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections. The most common reason for treatment discontinuation was disease progression (12%; n = 12).

In patients treated in the first-line setting, 36.4% experienced decreased PSA levels compared with 20% of patients in the second-line cohort and 14% in the third-line cohort. Total alkaline phosphatase levels decreased in 77% of patients in the first-line group, 82% in the second-line group and 60% in the third-line group, underscoring the enhanced efficacy of radium-223 as a front-line therapy, according to the researchers.

The most common reasons for treatment discontinuation of patients in this study were patient decision (9.3%), disease progression (12.4%), and adverse events (6.2%). In addition, 5% of patients in the second-line cohort and 12% of patients in the third-line cohort died before completing the injection course.

The most common treatment-related adverse events were hematological events (9.3%) and diarrhea (8.2%), bone pain (7.2%) and decreased appetite (7.2%).

The relatively low rate of treatment-related adverse events and lack of new safety concerns presented in this study demonstrates the safety of radium-223 under routine clinical practice in Taiwan treating bone metastases related to castration-resistant prostate cancer, according to the poster. A follow-up observation up to 2 years after initial injection is currently ongoing.

Reference

Pang ST, Huang CY, Huang CP, et al. Patient characteristics and safety of radium-223 dichloride in Taiwan: Analysis of real-world clinical practice. Presented at: 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023; San Francisco, CA. Abstract 119.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content